Back to results
US 8,278,295 B2Granted
Amino-heterocyclic compounds
AssigneePfizer Inc.
InventorsMichelle M. Claffey, Christopher J. Helal, Patrick R. Verhoest
Life of this patent
Estimating the term…
Abstract
The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, A, and n are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.
Claims11
A compound of Formula (I),
- or a pharmaceutically acceptable salt thereof, wherein:
- R1 is selected from the group consisting of
- (i) hydrogen,
- (ii) (C1-C4)alkyl,
- (iii) (C2-C4)alkenyl,
- (iv) (C2-C4)alkynyl,
- (v) (C1-C4)alkoxy,
- (vi) (C1-C4)haloalkyl,
- (vii) (C3-C6)cycloalkyl, optionally substituted with one to three substituents, the substituents being independently selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, halo, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, cyano, carboxy, and carbamoyl,
- (viii) 4 to 10 member heterocycloalkyl, optionally substituted with one to three substituents, the substituents being independently selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, halo, (C1-C4)haloalkyl, (C1-C4) haloalkoxy, cyano, carboxy, and carbamoyl,
- (ix) aryl, optionally substituted with one to three substituents, the substituents being independently selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, halo, (C1-C4)haloalkyl, (C1-C4) haloalkoxy, cyano, carboxy, and carbamoyl, and
- (x) heteroaryl, optionally substituted with one to three substituents, the substituents being independently selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, halo, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, cyano, carboxy, and carbamoyl;
- R2 is selected from the group consisting of hydrogen, (C1-C4)alkyl, (C1-C4) haloalkyl, cyano, and (C3-C6)cycloalkyl;
- R3 is selected from the group consisting of (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6) alkynyl, (C3-C8)cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, each of which optionally may be substituted with one to three substituents, the substituents being independently selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, halo, and (C1-C4)haloalkyl;
- n is 1 or 2;
- A is —CR4R5— or —CHRa—CHRb—;
- R4 is selected from the group consisting of
- (i) hydrogen,
- (ii) (C1-C7)alkyl,
- (iii) (C3-C8)cycloalkyl,
- (iv) 4 to 10 member heterocycloalkyl,
- (v) aryl, optionally substituted with one to three substituents, the substituents being independently selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, halo, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, (C3-C6) cycloalkyl, cyano, carboxy, and carbamoyl,
- (vi) heteroaryl, optionally substituted with one to three substituents, the substituents being independently selected from the group consisting of (C1-C4) alkyl, (C1-C4) alkoxy, halo, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, (C3-C6)cycloalkyl, cyano, carboxy, and carbamoyl, and
- (vii) LR6, wherein:
- L is selected from the group consisting of —CH2—, —NR7—, and —O—;
- R6 is aryl, heteroaryl, (C1-C8)alkyl, (C3-C8)cycloalkyl, 4 to 10 member heterocycloalkyl, or (C1-C6)alkoxy, each of which optionally may be substituted with one to three substituents, the substituents being independently selected from the group consisting of (C1-C4)alkyl, (C1-C4) alkoxy, halo, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, (C3-C6)cycloalkyl, cyano, carboxy, and carbamoyl;
- and
- R7 is hydrogen, methyl or ethyl;
- R5 is selected from the group consisting of hydrogen, hydroxyl, (C1-C4)alkoxy, halogen, and (C1-C6)alkyl;
- or R4 and R5, together with the carbon to which they are attached, form a cycloalkyl or heterocycloalkyl ring that optionally incorporates an oxo group and is optionally substituted with (C1-C8)alkyl, (C3-C8) cycloalkyl, halo, (C1-C8) alkoxy, or (C1-C3)haloalkyl;
- Ra is (C1-C4)alkoxy or R8—O—C(O)—, wherein R8 is (C1-C4)alkyl;
- and
- Rb is aryl, heteroaryl, or heterocycloalkyl, optionally substituted with halo, (C1-C8) alkyl, (C3-C8)cycloalkyl, (C1-C8)alkoxy, or (C1-C3) haloalkyl;
- or Ra and Rb, together with the carbons to which they are attached, form a cycloalkyl or heterocycloalkyl ring that optionally incorporates an oxo group and is optionally substituted with (C1-C8) alkyl, (C3-C8) cycloalkyl, halo, (C1-C8)alkoxy, or (C1-C3)haloalkyl.
31 more elements
A compound of formula I,
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.